Istituto Gentili's turnover is constantly and rapidly growing, demonstrating the quality of the therapeutic solutions offered and their value for clinical practice:
Founded in 1917, it is now part of the Mediolanum Farmaceutici group and its activity is focused on the oncology and oncohematology area.
Since 2017, the exclusive commitment to oncology has allowed the company to equip itself with an articulated product portfolio comprising:
Drugs
for the treatment of advanced breast cancer
Anticancer therapies
for non-Hodgkin's lymphoma
Supportive therapies
to prevent or improve conditions associated with the oncological disease: febrile neutropenia, oropharyngeal mucositis and cancer pain
Vision
Istituto Gentili wants to present and consolidate itself as a reliable partner of the oncologist to:
- build care pathways aimed at preventing and treating cancer and allowing patients and family members to make the best decisions for their health;
- offer high quality therapeutic solutions, capable of supporting an optimal all-round management of patients suffering from severe neoplasms.
Our pillars are:
innovation, transparency, centrality of the patient's needs, constant cooperation with the scientific community.
continuous search for solutions and tools to improve people's health and well-being.
attention to internal human resources, with the creation of a fertile and motivating work environment that fosters full personal and professional fulfilment.
The company has four strategic lines:
- High level management skills
- Focus on oncology, oncohematology and supportive therapies
- Partnerships with the main leaders in the reference markets
- Cooperation with the scientific community